Buy Trilactane eye drops 0.005% 2.5 ml vial 1pc.
  • Buy Trilactane eye drops 0.005% 2.5 ml vial 1pc.

Latanoprost

605 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$31.25
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

The active ingredient of the solution Prolatan - prostaglandin latanoprost, which is an analogue of prostaglandin F 2α. Its action leads to a decrease in intraocular pressure, which is achieved by increasing the outflow of aqueous humor (uveoscleral outflow). According to the results of clinical studies, the drug has no significant effect on the amount of produced intraocular moisture, does not affect the hematophthalmic barrier.


Source - the Moscow Eye Clinic website: http://mgkl.ru/patient/aptechka/prolatan

Indications

  • Increased intraocular pressure (increased IOP).
  • Open-angle glaucoma.

Composition

Active substance: latanoprost - 0.05 mg.

Auxiliary components: sodium monohydrate, benzalkonium chloride, disodium hydrogen phosphate, sodium chloride, water.

Latanoprost is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Trilactane eye drops
Prolatan Sentiss Pharma India eye drops
Xalatamax Jadran-Galensky Laboratories ao Croatia eye drops
Gomamax Kevelt AO Estonia drops
Glauprost K.O.Romparm Company S.R.L Romania eye drops
Xalatan Pfizer USA eye drops

No customer reviews for the moment.

Write your review

Write your review

Latanoprost

Dosage and Administration

For adult patients and children after 1 year, the standard dosage is one drop of Prolatan solution once a day in the affected eye conjunctival. The optimal effect is achieved if the drug is used in the evening. When skipping a dose, the next one is administered at the usual time.


Source - the Moscow Eye Clinic website: http://mgkl.ru/patient/aptechka/prolatan

Adverse reactions

  • The increase in the number, length and thickness of ciliary hair, darkening of the skin of the eyelids, changing the color of the iris, iritis, uveitis, macular edema ..
  • Blurred vision, discomfort in the eyes, conjunctival redness, punctate epithelial keratopathy, eyelid edema, crusts on the eyelids, photophobia, conjunctivitis, diplopia ..
  • Retinal detachment, in diabetic retinopathy of the vitreous hemorrhage ..
  • Respiratory tract infections, stenocardia, muscle pain, heart rhythm disturbances ..
  • Allergic reactions, rash ..
  • Bronchial asthma, bronchospasm, shortness of breath.

Contraindications

With care solution Prolatan should be appointed at: aphakia, pseudo-aphakia and rupture of the back capsule lens; macular edema (including anamnesis); congenital, neovascular, inflammatory glaucoma; asthma; herpetic keratitis.

Overdosage

For overdose with Prolatan solution, reddening of the conjunctiva and episclera, nausea, abdominal pain, sweating, flushing, fatigue, dizziness are characteristic. If necessary, symptomatic therapy should be carried out.

  • Brand name: Latanoprost
  • Active ingredient: Latanoprost

Studies and clinical trials of Latanoprost (Click to expand)

  1. Synthesis of latanoprost diastereoisomers
  2. Development and validation of a liquid chromatography/electrospray ionization tandem mass spectrometry method for the quantification of latanoprost free acid in rabbit aqueous humor and ciliary body
  3. Stability of latanoprost in an ophthalmic lipid emulsion using polyvinyl alcohol
  4. The Meyer–Schuster rearrangement: a new synthetic strategy leading to prostaglandins and their drug analogs, Bimatoprost and Latanoprost
  5. The additive effect of latanoprost 0.005% in patients on maximally tolerated medical therapy
  6. The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension
  7. Clinical experience with Latanoprost, a retrospective study of 153 patients
  8. Latanoprost 0.005% and anterior segment uveitis
  9. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension
  10. Latanoprost: Experience of 2-year treatment in Scandinavia
  11. Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes
  12. Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma
  13. The effect on diurnal intraocular pressure of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension
  14. Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol
  15. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study
  16. The short-term effect of latanoprost on intraocular pressure and pulsatile ocular blood flow
  17. Use of latanoprost to reduce acute intraocular pressure rise following neodymium: Yag laser iridotomy
  18. A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma
  19. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial
  20. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily
  21. Evaluation of retinal haemodynamics and retinal function after application of dorzolamide, timolol and latanoprost in newly diagnosed open-angle glaucoma patients
  22. Latanoprost Stimulates Eumelanogenesis in Iridial Melanocytes of Cynomolgus Monkeys
  23. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle
  24. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT™) versus latanoprost 0.005% (XALATAN™) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials

8 other products in the same category:

arrow_upward